A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA)
Latest Information Update: 26 Feb 2025
At a glance
- Drugs Tofacitinib (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Pfizer
Most Recent Events
- 20 Feb 2025 Status changed from active, no longer recruiting to completed.
- 20 Feb 2025 Status changed from active, no longer recruiting to completed.
- 07 Oct 2024 Planned End Date changed from 22 Mar 2025 to 12 Feb 2025.